Literature DB >> 24825873

A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.

Yuan Lin1, Jie Luo1, Weichao Eric Zhu2, Minu Srivastava3, Dorthe Schaue4, David A Elashoff5, Steven M Dubinett6, Sherven Sharma3, Benjamin Wu7, Maie A St John8.   

Abstract

OBJECTIVE: This study aimed to evaluate the therapeutic efficacy of a novel polymer platform delivering cisplatin and cytokines in the treatment of head and neck squamous cell carcinoma (HNSCC). STUDY
DESIGN: In vivo study.
SETTING: Academic research laboratory. SUBJECTS AND METHODS: Mice were randomized to receive implantation of (1) no polymer, (2) plain polymer, (3) plain polymer with local cisplatin injection, or (4) cisplatin polymer. The 2 groups of mice implanted with cisplatin polymer or no polymer were further randomized to receive (1) 4 Grays external beam radiation for 4 days or (2) no radiation. For cytokine studies, mice were grouped into (1) no polymer, (2) plain polymer, (3) plain polymer with intratumoral injection of recombinant CCL21 twice a week, (4) polymer containing parental dendritic cells, or (5) polymer containing dendritic cells secreting CCL21 (DC-CCL21).
RESULTS: The cisplatin-secreting polymer effectively reduced tumors in the mice by more than 16-fold (P < .01). We also observed a statistically significant lower tumor weight among mice treated with cisplatin polymer and concomitant radiation compared to control groups. The DC-CCL21 polymer reduced SCCVII/SF tumors in the C3H/HeJ mice by more than 41% (P < .01).
CONCLUSION: Herein, we demonstrate the efficacy of a novel polymer platform in delivering cisplatin and cytokines. We also demonstrate that we can effectively grow dendritic cells in the polymer that can actively secrete CCL21 for a minimum of 5 days. This polymer may represent a new therapeutic modality for patients with HNSCC. Once this polymer platform is optimized, we will plan to pursue prospective trials in patients with HNSCC. © American Academy of Otolaryngology—Head and Neck Surgery Foundation 2014.

Entities:  

Keywords:  head and neck cancer; novel therapeutics; polymer; squamous cell carcinoma

Mesh:

Substances:

Year:  2014        PMID: 24825873      PMCID: PMC4167678          DOI: 10.1177/0194599814533775

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  31 in total

1.  Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model.

Authors:  M A Kuriakose; F A Chen; N K Egilmez; Y S Jong; E Mathiowitz; M D DeLacure; W L Hicks; T L Loree; R B Bankert
Journal:  Head Neck       Date:  2000-01       Impact factor: 3.147

2.  Transgenic overexpression of the CC chemokine CCL21 disrupts T-cell migration.

Authors:  K W Christopherson; J J Campbell; R A Hromas
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

3.  The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model.

Authors:  D A Arenberg; A Zlotnick; S R Strom; M D Burdick; R M Strieter
Journal:  Cancer Immunol Immunother       Date:  2001-01       Impact factor: 6.968

4.  Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.

Authors:  S Sharma; M Stolina; L Zhu; Y Lin; R Batra; M Huang; R Strieter; S M Dubinett
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

5.  Polymer chemotherapy for head and neck cancer.

Authors:  A H Shikani; A J Domb
Journal:  Laryngoscope       Date:  2000-06       Impact factor: 3.325

6.  Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms.

Authors:  A P Vicari; S Ait-Yahia; K Chemin; A Mueller; A Zlotnik; C Caux
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

7.  Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.

Authors:  Srinivas S Somanchi; Anitha Somanchi; Laurence J N Cooper; Dean A Lee
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

8.  Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H mice.

Authors:  Aditi H Mandpe; Kangla Tsung; Jeffrey A Norton
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-07

9.  Microsurgical free flap reconstruction outcomes in head and neck cancer patients after surgical extirpation and intraoperative brachytherapy.

Authors:  Douglas A Ross; Jagdeep S Hundal; Yung H Son; Stephan Ariyan; Joseph Shin; Roger Lowlicht; Clarence T Sasaki
Journal:  Laryngoscope       Date:  2004-07       Impact factor: 3.325

10.  Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype.

Authors:  Jun Wang; Liqiang Xi; Jennifer L Hunt; William Gooding; Theresa L Whiteside; Zhuo Chen; Tony E Godfrey; Robert L Ferris
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

View more
  2 in total

1.  Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.

Authors:  Brittany J Poelaert; Svetlana Romanova; Shelby M Knoche; Madeline T Olson; Bailee H Sliker; Kaitlin Smits; Brittney L Dickey; Alexandra E J Moffitt-Holida; Benjamin T Goetz; Nuzhat Khan; Lynette Smith; Hamid Band; Aaron M Mohs; Donald W Coulter; Tatiana K Bronich; Joyce C Solheim
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

2.  CCL21 Cancer Immunotherapy.

Authors:  Yuan Lin; Sherven Sharma; Maie St John
Journal:  Cancers (Basel)       Date:  2014-05-07       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.